CORRECTING & REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver...
January 11 2016 - 10:19AM
Business Wire
Headline of release should read: Rosetta Genomics Granted EPO
Patent Allowance for Use of microRNA Molecules for the Treatment of
Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent
Allowance for Use of microRNA Molecules for the Treatment of Liver
Cancer). In addition, there is a change to the first paragraph,
first sentence. "U.S. Patent" should read "European Patent."
The corrected release reads:
ROSETTA GENOMICS GRANTED EPO PATENT
ALLOWANCE FOR USE OF MICRORNA MOLECULES FOR THE TREATMENT OF LIVER
CANCER
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announces that the European Patent Office (EPO) has granted a
patent allowance for patent application No. 08844596.0, relating to
“Targeting microRNAs for the Treatment of Liver Cancer.” This
patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The
patent claims chemically-modified, anti-microRNA molecules for use
in the treatment of liver cancer, including miR-21, miR-125a,
miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
“This patent allowance further bolsters our leading intellectual
property position in microRNA technology, providing us with
additional opportunities to monetize this expanding core asset,”
noted Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics. “Previously published pre-clinical data in
Clinical Research, a peer reviewed journal, supports the important
role that miRs like miR-191 may play in the treatment of
hepatocellular carcinoma, the most common form of liver cancer.
Liver cancer is a life-limiting disease for which there are
inadequate treatment options and, consequently, a poor prognosis.
We look forward to the advancement of clinical studies in pursuit
of microRNA targets as a potentially effective treatment for liver
cancer.”
“We are particularly encouraged by the expanding role of
microRNAs to fight various cancers. As with our recently announced
sublicense with Mirna Therapeutics, we are in a strong position to
leverage our extensive intellectual property position to help
advance the development of new and effective cancer treatments
while creating value from this growing asset,” added Mr.
Berlin.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Rosetta’s cancer testing
services are commercially available through the Philadelphia, PA-
and Lake Forest, CA-based CAP-accredited, CLIA-certified labs,
respectively. For more information visit www.rosettagx.com.
Rosetta Genomics Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including but not limited
to statements with respect to Rosetta’s potential to create
value by leveraging its intellectual property position, Rosetta
retaining rights to the relevant intellectual property to utilize
specific microRNAs, as well as Rosetta helping to advance
the development of new and effective cancer treatments constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta’s Annual Report on Form 20-F for the
year ended December 31, 2014 as filed with the Securities and
Exchange Commission (SEC). In addition, any forward-looking
statements represent Rosetta’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111005839/en/
Rosetta Genomics Contact:Ken Berlin,
609-419-9003President &
CEOinvestors@rosettagenomics.comorRosetta Genomics Investor
Contact:LHAAnne Marie Fields, 212-838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024